前传奇生物高管黄颖（Ying Huang）现执掌 K2 Therapeutics，该公司基于来自亚洲生物技术公司的八项药物资产而建立。为何它入选 Endpoints 11：https://endpoints.news/endpoints-11-2026-winner-k2-therapeutics-looks-to-marry-chinas-speed-with-global-expertise/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content= 错过了颁奖典礼？通过免费虚拟体验回顾精彩亮点和获奖者采访。
Ex-Legend Biotech exec Ying Huang now leads K2 Therapeutics, built on eight drug assets from biotechs in Asia. Why it made the Endpoints 11: https://endpoints.news/endpoints-11-2026-winner-k2-therapeutics-looks-to-marry-chinas-speed-with-global-expertise/?utm_source=Twitter&utm_medium=organic_social&utm_campaign=editorial&utm_content=
Missed the gala? Catch up on highlights and honoree interviews with the free virtual experience.
来源：Endpoints News · x.com